Abstract:While traditional β-blockers (i.e. competitive orthosteric antagonists of β-adrenergic receptors; βARs) are widely used as cardiovascular therapeutics, adverse effects such as fatigue and the nonselective inhibition of multiple receptor subtypes often limit maximal effectiveness. An emerging approach to enhance therapeutic targeting is to identify allosteric modulators that act cooperatively with orthosteric ligands. In contrast to orthosteric ligands which bind the endogenous ligand binding site, allosteric modulators bind to regions that are topographically distinct from the orthosteric pocket and can enhance (positive allosteric modulator; PAM) or reduce (negative allosteric modulator; NAM) the activities of orthosteric agonists/antagonists. Since allosteric regions exhibit greater sequence and structural diversity among receptor subtypes relative to the more highly conserved orthosteric pocket, allosteric modulators are more likely to be subtype specific and/or generate less adverse effects. We therefore embarked on a DNA-encoded small molecule library screen to identify novel allosteric modulators of the β 1 AR. Following multiple rounds of affinity selection using purified, functional, β 1 ARs reconstituted in lipid nanodiscs and HitGen’s OpenDEL® small molecule library containing more than 1 billion unique compounds, we identified Compound 11 (C11) as an allosteric modulator with unique pharmacological properties. Notably, C11 binds to the β 1 AR with micromolar affinity and enhances the binding affinity of orthosteric agonists and certain antagonists to the β 1 AR. In contrast to its positive cooperative effect on ligand binding, cell signaling assays showed C11 potently inhibits G protein and β-arrestin signaling downstream of the β 1 AR. Importantly, C11 showed high β 1 AR specificity with no effect on β 2 AR or AT 1 R signaling. These results suggest that C11 is a β 1 AR-specific PAM in terms of ligand binding but a NAM in terms of agonist efficacy, belonging to a largely under-characterized class of allosteric modulators termed PAM-antagonists. With an extremely unique pharmacological profile, C11 is a promising potential therapeutic and experiments evaluating its ability to modulate β 1 AR signaling in vivo are ongoing.

Discovery of Novel Antagonists on Β2-Adrenoceptor from Natural Products Using a Label-Free Cell Phenotypic Assay.

Identification of New Potent A1 Adenosine Receptor Antagonists Using a Multistage Virtual Screening Approach

Discovery of Β-Arrestin-biased Β2-Adrenoceptor Agonists from 2-Amino-2-phenylethanol Derivatives

Discovery of Novel Dual Adenosine A1/A2A Receptor Antagonists Using Deep Learning, Pharmacophore Modeling and Molecular Docking.

Label-free cell phenotypic profiling of histamine H4R receptor and discovery of non-competitive H4R antagonist from natural products

Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.

Pharmacophore Modeling of Dual Angiotensin II and Endothelin A Receptor Antagonists.

The Discovery of Novel α2a Adrenergic Receptor Agonists Only Coupling to Gαi/O Proteins by Virtual Screening

Insights into the Binding Modes of Human Β3-Adrenergic Receptor Agonists with Ligand-Based and Receptor-Based Methods

Synthesis and blocking activities of a new class of α₁-adrenoceptor antagonists.

Identification of Two Novel α1-AR Agonists Using a High-Throughput Screening Model

Identification Of Two Novel Alpha(1)-Ar Agonists Using A High-Throughput Screening Model

Receptor-based Molecular Modeling Study on Antagonist-Bound Human α1A, α1B and α1D-Adrenoceptors

Selective Discovery Of Gpcr Ligands Within Dna-Encoded Chemical Libraries Derived From Natural Products: A Case Study On Antagonists Of Angiotensin Ii Type I Receptor

Searching for the Novel Lead Compounds of alpha(1)-AR Antagonists (Part I): Design, Synthesis and Bioassay of 5-Chloro-2-[4-(aryloxyalkyl)piperazin-1-yl] benzo[d]oxazole Compounds

Screening and toxicity evaluation of natural compounds as adenosine 2a and 2b receptor ligands: insights from molecular docking, dynamics, and ADMET analysis

Abstract P2154: A Novel Allosteric Modulator of the Β 1 AR Identified by DNA-encoded Small Molecule Library Screening Demonstrates Unique Pharmacology and Function

Synthesis and biological activity evaluation of AT1 angiotensin II receptor antagonists of dibenzimidazoles with N-phenyl-1 H-pyrrole

Discovery and Identification of Novel 5-Hydroxy-4 H -benzo[1,4]oxazin-3-one Derivatives as Potent β 2 -Adrenoceptor Agonists through Structure-Based Design, Synthesis, and Biological Evaluation

QSAR Analysis of Human Adenosine A3 Receptor Antagonists

Discovery of a Highly Selective β 2 -Adrenoceptor Agonist with a 2-Amino-2-phenylethanol Scaffold as an Oral Antiasthmatic Agent